Myeloma therapies. A peak into the future

Research output: Contribution to journalArticlepeer-review


Multiple myeloma is a devastating hematologic cancer that is associated with significant comorbidities plaguing the clinical course of the disease. Recent development in myeloma therapeutics has made a positive impact in overall survival of patients. Several new drugs secured approval from the FDA in the last 5 years bringing renewed hope to patients and caregivers. What remains more promising is the combination of these new agents with traditional anti-myeloma therapies that are clinically demonstrating enhanced activity and improvement in the number of patients achieving complete responses. These high rates of clinical responses question the upfront use of high-dose chemotherapy and autologous stem cell transplant. The future of myeloma therapeutics resides in rational and effective combinations that can target both the tumor cell as well as its microenvironment.

Original languageEnglish (US)
Pages (from-to)75-78
Number of pages4
Issue numberSUPPL. 2
StatePublished - Sep 13 2007


  • Myeloma
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Myeloma therapies. A peak into the future'. Together they form a unique fingerprint.

Cite this